Development of a Microfluidic Platform for Blood Testing in Neonatal and Pediatric Patients STTR (R41)

The summary for the Development of a Microfluidic Platform for Blood Testing in Neonatal and Pediatric Patients STTR (R41) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Development of a Microfluidic Platform for Blood Testing in Neonatal and Pediatric Patients STTR (R41): This FOA encourages applications to develop microfluidic devices to analyze blood for factors related to the thrombotic, transfusion, and/or hemostatic status of pediatric/neonatal patients. Platforms should support clinical and/or research applications. Microfluidic designs that are multifunctional, with the capacity to perform multiple assays on a single blood sample, are of interest. Use of these devices could significantly reduce levels of phlebotomy-induced blood loss in pediatric/neonatal patients.

Federal Grant Title:	Development of a Microfluidic Platform for Blood Testing in Neonatal and Pediatric Patients STTR (R41)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-14-025
Type of Funding:	Grant
CFDA Numbers:	93.839
CFDA Descriptions:	Blood Diseases and Resources Research
Current Application Deadline:	Feb 10, 2014
Original Application Deadline:	Feb 10, 2014
Posted Date:	Nov 18, 2013
Creation Date:	Nov 18, 2013
Archive Date:	Mar 13, 2014
Total Program Funding:	$225,000
Maximum Federal Grant Award:	$225,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	1
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-14-025.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • An Intergenerational Precision Medicine Research Program for the Study of Factor VIII Immu...; • New Directions in Hematology Research (SHINE-II) (R01 Clinical Trial Optional); • Limited Competition: Sickle Pan-African Research Consortium Clinical Coordinating Center (...; • Sickle Pan-African Research Consortium Collaborative Sites (U01 Clinical Trial Optional); • Limited Competition: Sickle Africa Data Coordinating Center (U24 Clinical Trial Optional); • Improved Therapy for Hemophilia and Hereditary Bleeding Disorders; • Clinical Hematology Research Career Development Program (K12); • Molecular Mechanisms Underlying Diamond-Blackfan Anemia and Other Congenital Bone Marrow F...
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...